Stability of BPC-157 in solution: what has been measured — one year on posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Post #30 answers the question as asked. The question underneath it is different.
Distinguishing three things in the Stability of BPC-157 discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Stability of BPC-157 would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Stability in solution is the practical constraint. Dry, these keep well; reconstituted, the supplier's own data usually covers a shorter period than people assume.
Narrowing post #33, because the general version has more than one answer.
Storage after reconstitution is where most of the practical questions land. Refrigeration, minimal temperature cycling, protection from light, and using it inside the period the supplier's stability statement covers.
Worth one more sentence than it usually gets.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
Small point, but it is the one that usually catches people.
I will take the caveat as seriously as the claim, which is the point of putting it there.
Answering the question post #37 raises rather than the one it answers.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.
Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.
Written quickly, so the reasoning may be tighter than the wording.
The arithmetic in post #42 is right; the assumption feeding it is the part to check.
Reading back through the Stability of BPC-157 threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
Answering the question post #40 raises rather than the one it answers.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
Two people can read the same figure differently here and both be reasonable.
Good question, well framed, and I would like to see it answered properly.
On Stability of BPC-157: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
Everything in post #44 holds. The case it does not cover is the one I have.
My experience of Stability of BPC-157 contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
Confirming post #47 from a second method, which matters more than confirming it from a second person.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
I would put this at better than even and not much better.
I had written a reply contradicting post #48 and deleted it. Here is what survived.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
I would rather be precise about what I do not know than vague about what I do.
That is the distinction I keep failing to hold on to. Written down now.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
Speaking for myself and not for anyone else who has posted here.
Adding the measurement that post #51 says would settle it.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
Not the whole picture, but the part of it I can speak to.
Collapsed as off-topic by two members at trust level 3 or above
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
The variance between people here is larger than the effect being discussed.
Answering the question post #55 raises rather than the one it answers.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
Someone should write this up properly, and it should probably not be me.
The arithmetic in post #55 is right; the assumption feeding it is the part to check.
Where I would push back on the Stability of BPC-157 consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
I read post #55 twice before replying, because I had assumed the opposite.
Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
One more caveat and then I will stop qualifying: the sample selected itself.
Post #59 answers the question as asked. The question underneath it is different.
Solubility in this family is generally good, which means a vial that will not go into solution readily is telling you something about the material rather than about the technique.
Take it as a starting point and not as a specification.